UroGen Pharma (NASDAQ:URGN) Posts Quarterly Earnings Results, Misses Estimates By $0.11 EPS

UroGen Pharma (NASDAQ:URGN - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11), Zacks reports. The firm had revenue of $24.57 million for the quarter, compared to analyst estimates of $25.25 million.

UroGen Pharma Price Performance

UroGen Pharma stock traded up $0.08 on Thursday, reaching $10.90. The company's stock had a trading volume of 222,570 shares, compared to its average volume of 377,910. The company has a market cap of $255.65 million, a price-to-earnings ratio of -3.46 and a beta of 1.12. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The business's fifty day moving average price is $10.45 and its 200 day moving average price is $11.70. UroGen Pharma has a twelve month low of $9.03 and a twelve month high of $20.70.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. LADENBURG THALM/SH SH began coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They set a "buy" rating and a $31.00 price objective on the stock. D. Boral Capital restated a "buy" rating and set a $25.00 price objective on shares of UroGen Pharma in a research note on Monday. Finally, HC Wainwright reduced their target price on UroGen Pharma from $64.00 to $55.00 and set a "buy" rating on the stock in a report on Tuesday. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, UroGen Pharma currently has a consensus rating of "Buy" and an average target price of $38.20.

Remove Ads

Insider Activity at UroGen Pharma

In related news, General Counsel Jason Drew Smith sold 7,379 shares of the firm's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the sale, the general counsel now directly owns 26,468 shares in the company, valued at $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the sale, the insider now directly owns 145,666 shares in the company, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by company insiders.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.